Trending

leukaemia

Roche and AbbVie’s Venclexta approved in CLL

Roche and AbbVie’s Venclexta approved in CLL

Roche and AbbVie’s Venclexta (venetoclax) has been approved by the FDA in combination with Roche’s Gazyva (obinutuzumab) for

X

Roche and AbbVie’s Venclexta approved in CLL

https://pharmaphorum.com/news/roche-and-abbvies-venclexta-approved-in-cll/

Scotland says no to Yescarta, but backs Kymriah

Scotland says no to Yescarta, but backs Kymriah

Scotland’s cost-effectiveness watchdog has decided against making Gilead’s CAR-T therapy Yescarta routinely available to patients with two types

X

Scotland says no to Yescarta, but backs Kymriah

https://pharmaphorum.com/news/scotland-says-no-to-yescarta-but-backs-kymriah/

AbbVie, Roche eye first-line use of Venclexta in leukaemia

AbbVie, Roche eye first-line use of Venclexta in leukaemia

AbbVie and Roche’s Venclexta has hit the mark in a combination trial that could help it move into

X

AbbVie, Roche eye first-line use of Venclexta in leukaemia

https://pharmaphorum.com/news/abbvie-roche-venclexta-leukaemia/

Cancer Research UK gives $4m funding to Glasgow Uni CML project

Cancer Research UK gives $4m funding to Glasgow Uni CML project

Cancer Research UK granted £3.1m (nearly $4m) to a group of researchers at the University of Glasgow to

X

Cancer Research UK gives $4m funding to Glasgow Uni CML project

https://pharmaphorum.com/news/experimental-leukaemia-study-grant/

FDA grants leukaemia drug ‘breakthrough’ status

FDA grants leukaemia drug ‘breakthrough’ status

A leukaemia drug has been granted ‘breakthrough therapy’ status by the US drug regulator. Daiichi Sankyo announced that

X

FDA grants leukaemia drug ‘breakthrough’ status

https://pharmaphorum.com/market-access-2/fda-grants-leukaemia-drug-breakthrough-status/

Pfizer objects to NICE methods in leukaemia drug rejection

Pfizer objects to NICE methods in leukaemia drug rejection

NICE has caused controversy by rejecting Pfizer’s Besponsa – a blood cancer drug that can give patients the

X

Pfizer objects to NICE methods in leukaemia drug rejection

https://pharmaphorum.com/news/pfizer-questions-nice-methods-besponsa/

Spectacular early results for Novartis’ CAR-T combined with Imbruvica

Spectacular early results for Novartis’ CAR-T combined with Imbruvica

A combination of Novartis’ ‘next generation’ CAR-T drug CTL119 with Janssen and AbbVie’s Imbruvica has cleared all signs

X

Spectacular early results for Novartis’ CAR-T combined with Imbruvica

https://pharmaphorum.com/news/spectacular-early-results-novartis-car-t-combined-imbruvica/

Teva’s Trisenox approved in first line for APL

Teva’s Trisenox approved in first line for APL

First ever chemotherapy-free regimen for rare leukaemia.

X

Teva’s Trisenox approved in first line for APL

https://pharmaphorum.com/news/tevas-trisenox-approved-first-line-apl/

Gamida Cell’s cell therapy treatment gains breakthrough status

Gamida Cell’s cell therapy treatment gains breakthrough status

Regulator to expedite review of blood cancer treatment

X

Gamida Cell’s cell therapy treatment gains breakthrough status

https://pharmaphorum.com/news/gamida-cells-nicord-breakthrough/

1 2

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com